Natural Capsules Limited , a prominent player in the capsule manufacturing industry, has announced its financial results for the second quarter and first half of the fiscal year 2025-26, revealing a mixed performance across its standalone and consolidated operations.

Standalone Performance

On a standalone basis, Natural Capsules Limited demonstrated resilience in its core business. The company reported a revenue from operations of Rs. 4,458.02 lakhs for the quarter ended September 30, 2025, marking a slight increase from the previous quarter. The net profit for Q2 stood at Rs. 281.05 lakhs, showing an improvement over the preceding quarter.

For the six-month period, the company's standalone performance was noteworthy:

Consolidated Results and Subsidiary Performance

The consolidated financial picture, however, presented challenges:

The significant disparity between standalone profit and consolidated loss is primarily attributed to the performance of the company's subsidiary, Natural Biogenex Private Limited. The subsidiary, which commenced commercial operations on March 31, 2025, is yet to achieve its full revenue potential, contributing to higher consolidated losses.

Strategic Decision on Rights Issue

The Board of Directors of Natural Capsules Limited has decided not to subscribe to the rights issue of Natural Biogenex Private Limited. This decision was attributed to cash flow commitments from ongoing projects, indicating a strategic focus on managing financial resources effectively.

Segment Performance

The company's financial results also shed light on its segment-wise performance:

1. Capsules Segment:

   • Revenue for Q2 FY 2025-26: Rs. 4,458.02 lakhs
   • Segment Results (Profit before tax and interest): Rs. 514.96 lakhs

2. API Segment:

   • Revenue for Q2 FY 2025-26: Rs. 122.24 lakhs
   • Segment Results: Rs. 859.45 lakhs

The API segment, despite lower revenue, showed higher profitability compared to the capsules segment, indicating its potential as a growth driver for the company.

Financial Position

As of September 30, 2025, Natural Capsules Limited's consolidated balance sheet reflected:

• Total Assets: Rs. 41,995.52 lakhs
• Total Equity: Rs. 24,539.98 lakhs
• Total Liabilities: Rs. 17,855.50 lakhs

Outlook

While the standalone business remains profitable, the consolidated performance underscores the challenges faced by the subsidiary. The company's decision to abstain from the subsidiary's rights issue suggests a cautious approach to capital allocation, possibly focusing on strengthening its core operations and managing ongoing project commitments.

As Natural Biogenex Private Limited progresses towards achieving its full revenue potential, investors and stakeholders will likely keep a close watch on the consolidated performance in the coming quarters.

Natural Capsules Limited continues to navigate through a phase of strategic growth and operational consolidation, balancing the performance of its established capsules business with the evolving dynamics of its newer ventures in the pharmaceutical sector.

Natural Capsules Limited , a prominent player in the pharmaceutical industry, has made two significant announcements that could impact its operational structure and financial position.

Retirement of Chief Operating Officer

Natural Capsules Limited has disclosed the retirement of Mr. MVN Kutty, the company's Chief Operating Officer (COO). According to the company's filing with the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), Mr. Kutty's retirement is due to superannuation and will be effective from the close of business hours on September 30, 2025.

The retirement announcement was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided the following details in its regulatory filing:

Rights Issue for Material Subsidiary

In a separate announcement made on the same day, Natural Capsules Limited informed the stock exchanges about a significant development concerning its material subsidiary, Natural Biogenex Private Limited. The Board of Directors of Natural Biogenex Private Limited has approved a rights issue in their meeting held on September 30, 2025.

The key details of the rights issue are as follows:

This rights issue is expected to infuse additional capital into Natural Biogenex Private Limited, potentially strengthening its financial position and supporting its growth initiatives.

Both announcements were made by Pranjal Deshmukh, the Company Secretary & Compliance Officer of Natural Capsules Limited, in accordance with regulatory requirements. These developments may have implications for the company's operational strategy and financial outlook in the coming months.

Investors and stakeholders of Natural Capsules Limited are advised to take note of these announcements and assess their potential impact on the company's future performance.